Clinical Trial Detail

NCT ID NCT01577173
Title A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Genentech, Inc.
Indications

head and neck squamous cell carcinoma

Therapies

Cetuximab

Duligotuzumab

Age Groups: adult

No variant requirements are available.